Literature DB >> 25155038

Correlation of CLPTM1L polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population.

Yiqian Liang1, Asmitananda Thakur, Lei Gao, Ting Wang, Shuo Zhang, Hui Ren, Junhui Meng, Tingting Geng, Tianbo Jin, Mingwei Chen.   

Abstract

The implication of genetic factors in predisposition to cancer is a recognized fact. The Cleft lip and palate transmembrane 1-like (CLPTM1L) gene resides in a locus in the chromosome 5p15.33 region that is associated with lung cancer susceptibility and has a role in carcinogenesis. We conducted a case-control study in a Chinese population of 309 pathologically confirmed lung cancer patients and 310 controls to investigate the effect of variant genotypes within the CLPTM1L locus on susceptibility to lung cancer and sensitivity to cisplatin-based chemotherapy. We genotyped nine single nucleotide polymorphisms (SNPs) within the CLPTM1L locus and examined their correlation with lung cancer risk and treatment response using χ (2) and unconditional logistic regression analysis. We identified rs451360 as a novel SNP associated with lung cancer risk in the Chinese Han population. The "T" allele of rs451360 was associated with decreased risk of lung cancer (p = 0.007, odd ratio (OR) = 0.59, 95 % confidence interval (CI): 0.40-0.87). Significant multiplicative interactions were observed between gender and polymorphisms of rs402710, the "T/T" genotype of which was associated with decreased lung cancer risk in male patients (p = 0.016, OR = 0.35, 95 % CI: 0.17-0.73). CLPTM1L polymorphisms did not affect the tumor sensitivity to cisplatin combination chemotherapy in our study patients. The results of the present study suggest a potential association between CLPTM1L variants and lung cancer risk in the Chinese Han populations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25155038     DOI: 10.1007/s13277-014-2508-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci.

Authors:  Yong Yong Shi; Lin He
Journal:  Cell Res       Date:  2005-02       Impact factor: 25.617

2.  SNP genotyping using the Sequenom MassARRAY iPLEX platform.

Authors:  Stacey Gabriel; Liuda Ziaugra; Diana Tabbaa
Journal:  Curr Protoc Hum Genet       Date:  2009-01

3.  A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia.

Authors:  Helen E Speedy; Maria Chiara Di Bernardo; Georgina P Sava; Martin J S Dyer; Amy Holroyd; Yufei Wang; Nicola J Sunter; Larry Mansouri; Gunnar Juliusson; Karin E Smedby; Göran Roos; Sandrine Jayne; Aneela Majid; Claire Dearden; Andrew G Hall; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; Richard Rosenquist; Daniel Catovsky; James M Allan; Richard S Houlston
Journal:  Nat Genet       Date:  2013-12-01       Impact factor: 38.330

4.  Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.

Authors:  Giannicola D'Addario; Melania Pintilie; Natasha B Leighl; Ronald Feld; Thomas Cerny; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

5.  Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening.

Authors:  Robert A Smith; Vilma Cokkinides; Durado Brooks; Debbie Saslow; Mona Shah; Otis W Brawley
Journal:  CA Cancer J Clin       Date:  2011-01-04       Impact factor: 508.702

6.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.

Authors:  Florence Le Calvez; Anush Mukeria; Jay D Hunt; Olaf Kelm; Rayjean J Hung; Philippe Tanière; Paul Brennan; Paolo Boffetta; David G Zaridze; Pierre Hainaut
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

Review 7.  Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.

Authors:  Alex Chang
Journal:  Lung Cancer       Date:  2010-10-16       Impact factor: 5.705

8.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.

Authors:  Gloria M Petersen; Laufey Amundadottir; Charles S Fuchs; Peter Kraft; Rachael Z Stolzenberg-Solomon; Kevin B Jacobs; Alan A Arslan; H Bas Bueno-de-Mesquita; Steven Gallinger; Myron Gross; Kathy Helzlsouer; Elizabeth A Holly; Eric J Jacobs; Alison P Klein; Andrea LaCroix; Donghui Li; Margaret T Mandelson; Sara H Olson; Harvey A Risch; Wei Zheng; Demetrius Albanes; William R Bamlet; Christine D Berg; Marie-Christine Boutron-Ruault; Julie E Buring; Paige M Bracci; Federico Canzian; Sandra Clipp; Michelle Cotterchio; Mariza de Andrade; Eric J Duell; J Michael Gaziano; Edward L Giovannucci; Michael Goggins; Göran Hallmans; Susan E Hankinson; Manal Hassan; Barbara Howard; David J Hunter; Amy Hutchinson; Mazda Jenab; Rudolf Kaaks; Charles Kooperberg; Vittorio Krogh; Robert C Kurtz; Shannon M Lynch; Robert R McWilliams; Julie B Mendelsohn; Dominique S Michaud; Hemang Parikh; Alpa V Patel; Petra H M Peeters; Aleksandar Rajkovic; Elio Riboli; Laudina Rodriguez; Daniela Seminara; Xiao-Ou Shu; Gilles Thomas; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Stephen K Van Den Eeden; Jarmo Virtamo; Jean Wactawski-Wende; Zhaoming Wang; Brian M Wolpin; Herbert Yu; Kai Yu; Anne Zeleniuch-Jacquotte; Joseph F Fraumeni; Robert N Hoover; Patricia Hartge; Stephen J Chanock
Journal:  Nat Genet       Date:  2010-01-24       Impact factor: 38.330

9.  Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines.

Authors:  Oscar Vazquez-Mena; Ingrid Medina-Martinez; Eligia Juárez-Torres; Valeria Barrón; Ana Espinosa; Nicolás Villegas-Sepulveda; Laura Gómez-Laguna; Karem Nieto-Martínez; Lorena Orozco; Edgar Roman-Basaure; Sergio Muñoz Cortez; Manuel Borges Ibañez; Carlos Venegas-Vega; Mariano Guardado-Estrada; Angélica Rangel-López; Susana Kofman; Jaime Berumen
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

10.  Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.

Authors:  Michael A James; Weidong Wen; Yian Wang; Lauren A Byers; John V Heymach; Kevin R Coombes; Luc Girard; John Minna; Ming You
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

View more
  5 in total

1.  CLPTM1L gene rs402710 (C > T) and rs401681 (C > T) polymorphisms associate with decreased cancer risk: a meta-analysis.

Authors:  Jianzhou Tang; Changming Hu; Hua Mei; Liang Peng; Hui Li
Journal:  Oncotarget       Date:  2017-11-01

2.  The identification of two regulatory ESCC susceptibility genetic variants in the TERT-CLPTM1L loci.

Authors:  Liqing Zhou; Guobin Fu; Jinyu Wei; Juan Shi; Wenting Pan; Yanli Ren; Xiangyu Xiong; Jianhong Xia; Yue Shen; Hongliang Li; Ming Yang
Journal:  Oncotarget       Date:  2016-02-02

3.  Genetic variations in TERC and TERT genes are associated with lung cancer risk in a Chinese Han population.

Authors:  Gang Ye; Nan Tan; Chenyang Meng; Jingjie Li; Li Jing; Mengdan Yan; Tianbo Jin; Fulin Chen
Journal:  Oncotarget       Date:  2017-11-06

4.  CYP4F2 and CYP3A5 gene polymorphisms and lung cancer in Chinese Han population.

Authors:  Ruiqing He; Meng Li; Anqi Li; Wenhui Dang; Tian Yang; Jing Li; Ning Zhang; Tianbo Jin; Mingwei Chen
Journal:  Clin Exp Med       Date:  2020-04-30       Impact factor: 3.984

5.  Association between IL-1R2 polymorphisms and lung cancer risk in the Chinese Han population: A case-control study.

Authors:  Chaoying Wang; Chengsheng Zhang; Junnv Xu; Yongfu Li; Jie Wang; Hui Liu; Yueli Liu; Zhong Chen; Haifeng Lin
Journal:  Mol Genet Genomic Med       Date:  2019-03-20       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.